Cortexyme, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Casey Lynch
- Full Time Employees
- 55
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 269 E Grand Ave South San Francisco CA United States of America 94080
- IPO Date
- May 9, 2019
- CIK
- 0001662774
- Website
- cortexyme.com
- Similar Companies
- Business
- Cortexyme, Inc. (Nasdaq: CRTX) operates as a clinical-stage biopharmaceutical company focused on developing therapeutics targeting Porphyromonas gingivalis (P. gingivalis) and its gingipain proteases for degenerative diseases including Alzheimer's disease, periodontal disease, oral squamous cell carcinoma prevention, and coronavirus infections; its pipeline features investigational small-molecule gingipain inhibitors such as atuzaginstat (COR388), COR588, COR852, and COR803, with prior emphasis on brain-penetrant agents for neurodegeneration and inflammation reduction. Founded in 2012 and headquartered in South San Francisco, California, the company pursues clinical programs primarily in North America and Europe, serving patients with chronic inflammatory and neurodegenerative conditions through biomarker-driven trials and partnerships with academic and research organizations. In 2022, Cortexyme underwent a major strategic reorganization by acquiring Novosteo, Inc., a developer of bone-targeting therapeutics like NOV004 for rare skeletal diseases such as osteogenesis imperfecta, resulting in a name change to Quince Therapeutics, Inc. (Nasdaq: QNCX), leadership transition with Dirk Thye as CEO, and a pivot toward rare disease indications while out-licensing legacy neuroscience and antiviral assets; the combined entity maintained approximately $120 million in cash post-transaction to support pipeline advancement.
Financial Comparison: SQZ Biotechnologies (NYSE:SQZ) vs. Cortexyme (NASDAQ:CRTX)
Cortexyme (NASDAQ:CRTX) and SQZ Biotechnologies (NYSE:SQZ) Critical Review
Sorrento Therapeutics (NASDAQ:SRNE) and Cortexyme (NASDAQ:CRTX) Head to Head Analysis
Critical Contrast: Cortexyme (NASDAQ:CRTX) vs. Eloxx Pharmaceuticals (NASDAQ:ELOX)
Cortexyme (NASDAQ:CRTX) versus Eloxx Pharmaceuticals (NASDAQ:ELOX) Critical Contrast
Cortexyme (NASDAQ:CRTX) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Head to Head Survey
Cortexyme (NASDAQ:CRTX) vs. Prime Medicine (NYSE:PRME) Critical Review
Cortexyme (NASDAQ:CRTX) Stock Passes Above Two Hundred Day Moving Average – What’s Next?
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks
After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)
5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI
Cortexyme Stock Sinks After FDA Puts Application on Hold
Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND
Why Cortexyme Stock Imploded in 2021
3 Most-Shorted Stocks at 52-Week Lows to Buy
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors